Study of Influence of Formulation Variables on Drug Release: Optimization of Sustained Release Matrix Tablets of Metoclopramide HCl Using Central Composite Experimental Design
AbstractMetoclopramide Hydrochloride (MCP), has a short half-life. In order to maintain therapeutic levels in blood, it administered in dose of 10-15 mg four times a day. Fluctuation in plasma concentration of drug is commonly observed for drugs that are rapidly absorbed and eliminated when used in long term therapy. This attribute makes metoclopramide a suitable candidate for controlled release delivery. In this work HPMC K4M was used as release rate controlling polymer for the development of controlled release tablet formulation. Experimental Design using CCRD was utilized to determine the influence of varying the concentration of different variables such as polymer and diluents on the release behavior of the drug from matrix tablets and optimization of formulation. Different SR formulation prepared were designed and optimized with the help of software Design Expert® version 10. Using Central Composite Rotatable Design (CCRD), fifteen formulations were selected and prepared using HPMC K4M, Avicel PH-102 and Lactose DC as variables. All the trial formulations were evaluated using different pharmacotechnical tests including hardness, friability, disintegration, dissolution. Online Dissolution apparatus type II and 900 ml different dissolution media in the pH range 1-6.8 and distilled water for dissolution. The drug release was studied by applying the dissolution models by DDSolver® software. Hixson-Crowell model was best fit to the F13 SR formulation. The CCRD experimental design was successfully used in optimization of sustained release Metoclopramide HCl formulation.
. R. C. Rowe, P. J. Sheskey, S. C. Owen, and A. P. Association, Handbook of pharmaceutical excipients. Pharmaceutical press London, 2006.
. B. Rotthäuser, G. Kraus, and P. C. Schmidt, "Optimization of an effervescent tablet formulation containing spray dried L-leucene glycol 6000 as lubricant using a central composite design " Eur J Pharm Biopharm, vol. 46, no. 1, pp. 85-94, 1998.
. G. E. P. Box and D. W. Behnken, "Some new three level designs for the study of quantitative variables," Technometrics, vol. 2 no. 4, pp. 455–475, 1960.
. (2004). Resistance to crushing of tablets
. USP, Ed. "United States Pharmacopoeia 30 and National Fomulary 25." The United States Pharmacopoeial Convention,CD ROM, 2007.
. T. Higuchi, "Mechanism of sustained-action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices," J. Pharm. Sci vol. 52 no. 12, pp. 1145–1149, 1963.
. P. Costa and J. M. S. Lobo, "Modeling and comparison of Dissolution profile," European Journal of Pharmaceutical Sciences vol. 13, no. 2, pp. 123-133, 2001.
. A. W. Hixson and J. H. Crowell, "Dependence of reaction velocity upon surface and agitation," Ind. Eng. Chem, vol. 23 no. 8, pp. 923–931, 1931
. H. M. Abdou, "Theory of Dissolution " in Dissolution ,Bioavailibility, and Bioequivalence, A. Gennaro, B. Migdalof, G. L. Hassert, and T. Medwick, Eds., ed. Easton ,Pennsylvnia 425: Mack Publishing Company 1989.
. R. W. Korsmeyer, R. Gurny, E. M. Doelker, P. Buri, and N. A. Peppas, "Mechanism of solute release from porous hydrophilic polymers," Int. J.Pharm, vol. 15, pp. 25–35, 1983.
. N. Aslan, "Application of response surface methodology and central composite rotatable design for modeling and optimization of a multi gravity separator for chromite concentration," Powder Technology, vol. 185, pp. 80-86, 2008.
. S. Schiermeier and P. C. Schmidt, "Fast dispersible Ibuprofen tablets," European Journal of Pharmaceutical Sciences vol. 15, pp. 295-305, 2002.
. S. G. Late, Y. Y. Yu, and A. K. Banga, "Effect of disintegration-promoting agent, lubricants and moisture treatment on optimized fast disintegrating tablets," Internation Journal of Pharmaceutics, vol. 365, pp. 4-11, 2009.
. G. S. Rekhi, R. V. Nellore, A. S. Husain, L. G. Tillman, H. J. Malinowski, and L. L. Ausberger, "Identification of critical formulations and processing variables for metoprolol tartrate extended release (ER) matrix tablets," Journal of Controlled Release, vol. 59, no. 3, pp. 327-342, 1999.
. U. P. XXVIII, " Rockville, MD, USA," Pharmacopeial Convention pp. pp. 19, .2412, 2745, 2005.
. H. Nyqvist, M. Nicklasson, and P. Lungren, "Studies on the physical properties of tablets and tablet excipients.V. Film coating for protection of a light-sensitive tablet formulation," Acta Pharmaceutica Suecica, vol. 19, p. 223, 1982.
. U. Convention, "United States Pharmacopoeia dispensing information: USP DI. United States Pharmacopoeial Convention " 1997.
. V. Shah, S. S. Patel, R. K. Jatav, A. Jain, and R. V. S. Int, "Formulation and evalution of mouth dissolving tablets of metoclopramide hydrochloride by direct compression technique," International Journal of Drug Discovery and Herbal Research (IJDDHR), vol. 1, no. 2, pp. 100-103, 2011.
. N. Yuksel, A. E. Kanik, and T. Baykara, "Comparison of in vitro dissolution profiles by ANOVA-based model dependent and independent methods," International Journal of Pharmaceutics, vol. 209, no. 1-2, pp. 57-67, 2000.
. (1997). Guidance for Industry Extended release oral dosage forms: development, evaluation and applications of in vitro/in vivo correlations.
. A. Tandya, R. Mammuucari, F. Dehghani, and N. R. Foster, "Danse gas processing of polymeric controlled release formulations," International Journal of Pharmaceutics, vol. 328, no. 1-11, 2007.
. K. R. Reddy, S. Mutalik, and S. Reddy, "Once-daily Sustained Release Matrix Tablets of Nicorandil:Formulation and In Vitro Evaluation," AAPS PharmSciTech, vol. 4, no. 4, p. E61, 2003.
. E. I. Hasan, B. I. Amrob, T. Arafatc, and A. A. Badwan, "Assessment of a controlled release hydrophilic matrix formulation for metoclopramide HCl," European Journal of Pharmaceutics and Biopharmaceutics, vol. 55 pp. 339–344, 2003.
. U. Mandal and T. K. Pal, "Sustained release of metformin HCl from hydroxy propyl methyl cellulose matrices: Formulation and in vitro evaluation," Asian J. Chem, vol. 20, no. 2, pp. 1163-1174, 2008.
. H. A. Merchant, H. M. Shoaib, J. Tazeen, and R. I. Yousaf, "Once-Daily Tablet Formulation and In Vitro Release Evaluation of Cefpodoxime Using Hydroxypropyl Methylcellulose: A Technical Note," AAPS PharmSciTech, vol. 7, no. 3, pp. E1-E5, 2006.
. M. H. Shoaib et al., "Development and Evaluation of Hydrophilic Colloid Matrix of Famotidine Tablets," AAPS PharmSciTech, vol. 11, no. 2, pp. 708-718, 2010.
. S. I. Abdel-Rahman, G. M. Mahrous, and M. El-Badry, "Preparation and comparative evaluation of sustained release metoclopramide hydrochloride matrix tablets," Saudi Pharmaceutical Journal, vol. 17, no. 4, pp. 283-288, 2009.
. E. Hasan, B. Amro, T. Arafat, and A. Badwan, "Assessment of a controlled release hydrophilic matrix formulation for metoclopramide HCl," Eur J Pharm Biopharm, vol. 55, no. 3, pp. 339-44, 2003.
. M. H. Shoaib, J. Tazeen, H. A. Merchant, and R. I. Yousaf, "Evaluation of drug release kinetics fro ibuprofen matrix tablets using HPMC," Pak. J. Pharm. Sci vol. 19, no. 2, pp. 119-124, 2006.
. V. Sankar, K. Ruckmani, K. Velayutham, and M. Nithyananth, "Comparative evaluation of zidovudine tablets formulated using natural andsemi synthetic binder," Acta Pharmaceutica Sciencia vol. 52, pp. 263-268, 2010.
. J. E. Polli, G. S. Rekhi, L. L. Augsburger, and V. P. Shah, "Methods to compare dissolution profiles and a rationale for wide dissolution specifications for metoprolol tartrate tablets," J Pharm Sci, vol. 86, no. 6, pp. 690-700, 1997.
. P. R. Radhika, T. K. Pala, and T. S. Kumar, "Formulation and Evaluation of Sustained Release Matrix Tablets of Glipizide," Iranian Journal of Pharmaceutical Sciences, vol. 5, no. 4, pp. 205-214, 2009.
. D. N. Venkatesh, S. Sankar, S. N. Meyyanathan, K. Elango, B. Suresh, and K. Santhi, "Design and Development of Prochlorperazine Maleate Sustained Release Tablets: Influence of Hydrophilic Polymers on the Release rate and In vitro Evaluation," International Journal of Pharmaceutical Sciences and Nanotechnology, vol. 3, no. 2, 2010.
. B. Shiyani, S. Gattani, and S. Surana, "Formulation and Evaluation of Bi-layer Tablet of Metoclopramide Hydrochloride and Ibuprofen," AAPS PharmSciTech, vol. 9 no. 3, pp. 818–827, 2008.
. S. Basak, B. J. Reddy, and K. L. Mani, "Formulation and release behaviour of sustained release ambroxol hydrochloride HPMC matrix tablet," Indian Journal of Pharmaceutical Sciences, vol. 68, no. 5, pp. 594-598, 2006.
Copyright (c) 2020 American Scientific Research Journal for Engineering, Technology, and Sciences (ASRJETS)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors who submit papers with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
- By submitting the processing fee, it is understood that the author has agreed to our terms and conditions which may change from time to time without any notice.
- It should be clear for authors that the Editor In Chief is responsible for the final decision about the submitted papers; have the right to accept\reject any paper. The Editor In Chief will choose any option from the following to review the submitted papers:A. send the paper to two reviewers, if the results were negative by one reviewer and positive by the other one; then the editor may send the paper for third reviewer or he take immediately the final decision by accepting\rejecting the paper. The Editor In Chief will ask the selected reviewers to present the results within 7 working days, if they were unable to complete the review within the agreed period then the editor have the right to resend the papers for new reviewers using the same procedure. If the Editor In Chief was not able to find suitable reviewers for certain papers then he have the right to accept\reject the paper.B. sends the paper to a selected editorial board member(s). C. the Editor In Chief himself evaluates the paper.
- Author will take the responsibility what so ever if any copyright infringement or any other violation of any law is done by publishing the research work by the author
- Before publishing, author must check whether this journal is accepted by his employer, or any authority he intends to submit his research work. we will not be responsible in this matter.
- If at any time, due to any legal reason, if the journal stops accepting manuscripts or could not publish already accepted manuscripts, we will have the right to cancel all or any one of the manuscripts without any compensation or returning back any kind of processing cost.
- The cost covered in the publication fees is only for online publication of a single manuscript.